Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.

about

Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.

Item

http://www.wikidata.org/entity/Q40453735

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Prognostic significance of equ ...... breast cancer: A cohort study.

@en

type

Item

label

Prognostic significance of equ ...... breast cancer: A cohort study.

@en

prefLabel

Prognostic significance of equ ...... breast cancer: A cohort study.

@en

P1476

Prognostic significance of equ ...... breast cancer: A cohort study.

@en

P2093

Asha S Multani

http://www.w3.org/2001/XMLSchema#string

Kenneth R Hess

http://www.w3.org/2001/XMLSchema#string

Nour Sneige

http://www.w3.org/2001/XMLSchema#string

Nuhad K Ibrahim

http://www.w3.org/2001/XMLSchema#string

Yun Gong

http://www.w3.org/2001/XMLSchema#string

P2860

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.

Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells.

High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Adv

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy

P304

1115-1123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.30460

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27893937

http://www.w3.org/2001/XMLSchema#string

P932

5372352

http://www.w3.org/2001/XMLSchema#string